Effectiveness of Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes Duration: Interim Report of the ASSIGN-K Study

BACKGROUND: Ipragliflozin is a selective sodium glucose co-transporter 2 inhibitor. The ASSIGN-K study is investigating the efficacy and safety of ipragliflozin for type 2 diabetes mellitus (T2DM) in the real-world clinical setting. METHODS: Japanese T2DM patients with inadequate glycemic control de...

Descripción completa

Detalles Bibliográficos
Autores principales: Iemitsu, Kotaro, Kawata, Takehiro, Iizuka, Takashi, Takihata, Masahiro, Takai, Masahiko, Nakajima, Shigeru, Minami, Nobuaki, Umezawa, Shinichi, Kanamori, Akira, Takeda, Hiroshi, Ito, Shogo, Kikuchi, Taisuke, Amemiya, Hikaru, Kaneshiro, Mizuki, Mokubo, Atsuko, Takuma, Tetsuo, Machimura, Hideo, Tanaka, Keiji, Asakura, Taro, Kubota, Akira, Aoyanagi, Sachio, Hoshino, Kazuhiko, Ishikawa, Masashi, Matsuzawa, Yoko, Obana, Mitsuo, Sasai, Nobuo, Kaneshige, Hideaki, Minagawa, Fuyuki, Saito, Tatsuya, Shinoda, Kazuaki, Miyakawa, Masaaki, Tanaka, Yasushi, Terauchi, Yasuo, Matsuba, Ikuro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5544486/
https://www.ncbi.nlm.nih.gov/pubmed/28811858
http://dx.doi.org/10.14740/jocmr3116w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5544486/
https://www.ncbi.nlm.nih.gov/pubmed/28811858
http://dx.doi.org/10.14740/jocmr3116w

Ejemplares similares